Equities researchers at Barclays began coverage on shares of Insmed (NASDAQ:INSM – Get Free Report) in a note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set an “overweight” rating and a $231.00 price target on the biopharmaceutical company’s stock. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Following the transaction, the chief financial officer directly owned 80,506 shares of the company’s stock, valued at approximately $14,021,730.02. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 80 shares in the last quarter.